Name:
3DMN-2020-015
Description:
3DMN-2020-015
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/dcb80dda-fd87-40dc-9450-bdf921a9c42a/thumbnails/dcb80dda-fd87-40dc-9450-bdf921a9c42a.png
Duration:
T00H05M11S
Embed URL:
https://stream.cadmore.media/player/dcb80dda-fd87-40dc-9450-bdf921a9c42a
Content URL:
https://asa1cadmoremedia.blob.core.windows.net/asset-822b286d-f487-4a3c-b9da-2676dadaba09/Mohit Chhaya V3.1.mp4
Upload Date:
2020-06-05T11:02:17.5470000Z
Transcript:
Language: EN.
Segment:1 Interview with Mohit Chhaya (Bellaseno, Leipzig, Germany).
MOHIT CHAYA: So my name is Mohit Chhaya, and I am one of the Co-Founders and the CTO of BellaSeno. At BellaSeno, we engineer a new generation of breast implants so there are alternatives to silicone implants and the idea is that these are made with 3D printing technologies and over time, they get absorbed by the body, and they regenerate the breast tissue. So the idea is that after 2 years, when the implant gets absorbed, you are left with the natural tissue. So my role at BellaSeno is to direct the technological strategy, bring the company through the paths of regulations and certifications, and bring it to the market.
Segment:2 3D printing technologies and regenerative medicine.
MOHIT CHAYA: So 3D printing technologies are very core of what we do at BellaSeno. While we don't make custom, patient-specific breast scaffolds, what we do is, our scaffolds are very porous to allow for vascularization infill into the core of the device and these kind of intricate architectures are impossible to make with the traditional milling, turning or injection molding technology. So in that way, BellaSeno wouldn't exist if there was no 3D printing technology out there. On the other hand, you have regenerative medicine and there's people - very talented scientists - studying wound healing responses, how does soft tissue remodel over time? How does vascularization penetrate the core of a scaffold? We take all of this knowledge - all of the background that we've developed over the last 10 years - and build it into the design of the product itself to give it the best chance of performance. So both 3D printing and regenerative medicine are very central to the core of BellaSeno.
Segment:3 Engineering strategies to benefit the surgical community.
MOHIT CHAYA: So our vision is to change the current paradigm of health care from sustaining life to regenerating health. So what we focus on are inherently safe materials that have been used in the community for a long time, and then focus on the engineering aspects, to give the properties of the intended application. So what we think is that if more and more companies follow our principle of looking at safe materials and using engineering principles to get to the intended purpose, we think that the wider surgical community, of course, would benefit not only from faster product development, but also inherently safe therapies for the patient at large.
Segment:4 Delivering a 3D-printed device into an uncertain regulatory environment.
MOHIT CHAYA: So it's a very interesting journey that we've been on. We spent more than 10 years developing, from a scientific/academic point of view, the technology. But the work, that's only part of the equation. There's a lot of considerations when you bring something to the market all the way from how do you de-risk the technology to how do you perform your preclinical, your clinical validations, and so on. One of the biggest things that I've learned in this journey is to get the right stakeholders at a very early point in your development process. Get your surgeons involved. Get the regulators involved. Work along with the engineers, and so on. That's when you begin to see problems before they become truly big, and you catch them early on the process. The other important thing that I've learned is that to always keep in constant communication with the regulatory bodies as well, because it's a new area, 3D printing. Everyone's, in a way, learning as well. So it helps, then, to keep them in the loop, and also get their feedback on how do you then develop the technology, what kind of testings, validations do you perform, and so on.
Segment:5 The future of bioresorbable implants and custom devices.
MOHIT CHAYA: It's a very rapidly growing field. So first thing that I would see developing in the relatively short term is, at the moment, you have devices where you have a component for the structural things and a bioactive element on the other side and the surgeon combines them at the point of use. I see these ones to have these new composite materials with new manufacturing technologies coming through, allowing a hybrid structure. Or also, from the other side, you have these custom-made devices and more and more surgeons are getting used to the fact that you can have these imaging technologies in their clinic and there are companies, ecosystems, out there that can actually make these custom devices for their patients. The last thing I see is the way in which we design the structures is radically changing. You have a whole new generation of engineers who are trained to think in 3D. So they think in terms of very intricate geometries inspired by nature, biometric architectures that you don't normally see from the traditional milling or turning processes. Whereas now, these days you see these very talented engineers, and we've been very lucky at BellaSeno to have some of these engineers on our team who are, from the get-go, they only think in terms of 3D-printed porous architectures, and so on. So I see the look, the lightweighting of the implants, or porosity, and so on, to be a very important thing in the future. [MUSIC PLAYING]
Form Title Download
Form Title Bookmark
Form Title Share
Form Title Cite
